GILEAD SCIENCES, INC. Accumulated Other Comprehensive Income
GILEAD SCIENCES, INC. (GILD) had Accumulated Other Comprehensive Income of $95.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $95.00M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $78.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $39.00M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $36.00M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $95.00M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $78.00M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $39.00M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $36.00M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | -$18.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $92.00M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $132.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $73.00M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $93.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $69.00M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $28.00M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $31.00M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $10.00M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | -$20.00M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $2.00M 10-K · filed 2024-02-23 | |
| 2022-09-30 | $98.00M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $87.00M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $73.00M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $83.00M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $74.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $39.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $38.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$60.00M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $23.00M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $70.00M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $46.00M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $85.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $117.00M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $102.00M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $130.00M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $80.00M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $36.00M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.00M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | -$170.00M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $165.00M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $249.00M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $120.00M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $260.00M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $278.00M 10-K · filed 2018-02-27 | |
| 2016-09-30 | -$108.00M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | -$46.00M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | -$164.00M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $88.00M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $167.00M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $247.00M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $539.00M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $301.00M 10-K · filed 2016-02-24 | |
| 2014-09-30 | $173.96M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | -$41.46M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | -$95.77M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | -$124.00M 10-K · filed 2016-02-24 | -$124.45M 10-K · filed 2014-02-25 |
| 2013-09-30 | -$42.07M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $30.37M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $20.81M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | -$46.00M 10-K · filed 2015-02-25 | -$45.62M 10-K · filed 2013-02-27 |
| 2012-09-30 | $28.25M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $124.38M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $33.59M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $58.20M 10-K · filed 2013-02-27 | |
| 2011-09-30 | -$15.54M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | -$133.28M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | -$101.18M 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $30.91M 10-K · filed 2012-02-23 | |
| 2010-09-30 | $7.49M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $189.62M 10-Q · filed 2010-08-09 | |
| 2010-03-31 | $83.47M 10-Q · filed 2010-05-10 | |
| 2009-12-31 | -$5.76M 10-K · filed 2011-02-28 | |
| 2009-09-30 | -$39.20M 10-Q · filed 2009-11-05 | |
| 2009-06-30 | $23.29M 10-Q · filed 2009-08-05 | |
| 2008-12-31 | $41.24M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |